Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer

被引:90
作者
Prutki, Maja
Poljak-Blazi, Marija
Jakopovic, Marko
Tomas, Davor
Stipancic, Igor
Zarkovic, Neven
机构
[1] Rudjer Boskovic Inst, Div Mol Med, Lab Oxidat Stress, HR-10000 Zagreb, Croatia
[2] Univ Zagreb, Sch Med, Zagreb 41001, Croatia
[3] Univ Zagreb, Clin Hosp Sestre Milosrdnice, Zagreb, Croatia
[4] Univ Zagreb, Dubrava Univ Hosp, Zagreb, Croatia
关键词
colon carcinoma; transferrin receptor 1; ferritin; iron metabolism; metastasis;
D O I
10.1016/j.canlet.2005.07.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, the level and distribution of transferrin receptor 1 (TfR1) and ferritin in colorectal carcinoma and in normal colon epithelium has been determined relative to the tumor stage and iron status of patients using immunohistochemical staining methods. While the majority of carcinoma patients were anemic, no relationship between the level of colon tissue ferritin and TfR1 and the systemic parameters of iron metabolism was evident. Furthermore, no association between ferritin content and the grade of colorectal carcinoma was observed. However, a relationship between the expression of TfR1 and the grade of colorectal carcinoma was observed. In this case high expression of TfR1 was found in colorectal carcinoma samples of Dukes A or B grade, and well differentiated colorectal carcinoma cells. In comparison, weak or no expression of TfR1 was observed in carcinoma samples of Dukes C or D grade with poorly differentiated cells and in carcinoma samples that had lymph node infiltration and distant metastasis. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:188 / 196
页数:9
相关论文
共 37 条
[1]   Associated changes of lipid peroxidation and transforming growth factor β1 levels in human colon cancer during tumour progression [J].
Biasi, F ;
Tessitore, L ;
Zanetti, D ;
Cutrin, JC ;
Zingaro, B ;
Chiarpotto, E ;
Zarkovic, N ;
Serviddio, G ;
Poli, G .
GUT, 2002, 50 (03) :361-367
[2]   Cancer-related anemia:: Pathogenesis, prevalence and treatment [J].
Birgegård, G ;
Aapro, MS ;
Bokemeyer, C ;
Dicato, M ;
Drings, P ;
Hornedo, J ;
Krzakowski, M ;
Ludwig, H ;
Pecorelli, S ;
Schmoll, H ;
Schneider, M ;
Schrijvers, D ;
Shasha, D ;
Van Belle, S .
ONCOLOGY, 2005, 68 :3-11
[3]  
BLATT J, 1989, CANCER RES, V49, P2925
[4]  
CHITAMBAR CR, 1988, BLOOD, V72, P1930
[5]   MODULATION OF T-LEUKEMIC-CELL PHENOTYPE WITH PHORBOL ESTER [J].
DELIA, D ;
GREAVES, MF ;
NEWMAN, RA ;
SUTHERLAND, DR ;
MINOWADA, J ;
KUNG, P ;
GOLDSTEIN, G .
INTERNATIONAL JOURNAL OF CANCER, 1982, 29 (01) :23-31
[6]  
FAULK WP, 1980, LANCET, V2, P390
[7]  
Gackowski D, 2002, ACTA BIOCHIM POL, V49, P269
[8]  
GRAZIADEI I, 1994, BLOOD, V83, P260
[9]  
GRIFFIN MR, 1987, CANCER-AM CANCER SOC, V60, P2318, DOI 10.1002/1097-0142(19871101)60:9<2318::AID-CNCR2820600934>3.0.CO
[10]  
2-B